Uncategorized
STAT+: In pancreatic cancer, Patrick Soon-Shiong makes promises he has not kept
This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
I am entirely enthralled by the World Cup. I am watching a ton of soccer on TV. I love the Tartan Army that has invaded Boston for Scotland’s games at Gillette Stadium. Tiny Cape Verde drawing mighty Spain was incredible. Messi, 39, playing in his sixth (!) World Cup, is still the GOAT.
And England still hasn’t played but will in a couple of hours, as I get this newsletter finished on Wednesday afternoon. Olé!
Programming note: This newsletter is taking a holiday next week but will be back in your inboxes July 2.
What Soon-Shiong says vs. what he has delivered
I’ve taken a good bit of heat (and hate) from online fans of Patrick Soon-Shiong who view the billionaire physician as a selfless scientist/entrepreneur trying to rid the world of cancer. That’s a laudable goal, of course, except Soon-Shiong’s proclamations are mostly fluff, financially self-serving and have led to FDA wrist-slapping.
A wide gap exists between what Soon-Shiong says his cancer drugs can achieve and what they actually do, based on real clinical evidence.
Pancreatic cancer is an instructive and presently relevant example. Long before Soon-Shiong became rich and famous, he treated diabetic patients with pancreas transplants and performed surgery on patients with pancreatic cancer. A desire to transform the treatment of pancreatic cancer with novel immunotherapies inspired Soon-Shiong’s “Bioshield” mission, according to his own treatise.
This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
I am entirely enthralled by the World Cup. I am watching a ton of soccer on TV. I love the Tartan Army that has invaded Boston for Scotland’s games at Gillette Stadium. Tiny Cape Verde drawing mighty Spain was incredible. Messi, 39, playing in his sixth (!) World Cup, is still the GOAT.
And England still hasn’t played but will in a couple of hours, as I get this newsletter finished on Wednesday afternoon. Olé!
Programming note: This newsletter is taking a holiday next week but will be back in your inboxes July 2.
What Soon-Shiong says vs. what he has delivered
I’ve taken a good bit of heat (and hate) from online fans of Patrick Soon-Shiong who view the billionaire physician as a selfless scientist/entrepreneur trying to rid the world of cancer. That’s a laudable goal, of course, except Soon-Shiong’s proclamations are mostly fluff, financially self-serving and have led to FDA wrist-slapping.
A wide gap exists between what Soon-Shiong says his cancer drugs can achieve and what they actually do, based on real clinical evidence.
Pancreatic cancer is an instructive and presently relevant example. Long before Soon-Shiong became rich and famous, he treated diabetic patients with pancreas transplants and performed surgery on patients with pancreatic cancer. A desire to transform the treatment of pancreatic cancer with novel immunotherapies inspired Soon-Shiong’s “Bioshield” mission, according to his own treatise.
Uncategorized
Nirrin Technologies and S.T. Japan Partner on Next-Gen Protein Quantitation Tech
Nirrin Technologies and S.T. Japan Partner on Next-Gen Protein Quantitation Tech
Nirrin Technologies appointed S.T. Japan as its exclusive distribution partner for the TALOSTM protein quantitation system in Japan. The Japanese company will purchase a TALOS demonstration system, establishing local evaluation capabilities that will allow prospective customers throughout Japan to assess the technology using their own samples and workflows.
“Japan is one of the world’s leading centers for biopharmaceutical innovation and manufacturing,” according to Bryan Hassell, PhD, CEO of Nirrin Technologies. “S.T. Japan has built a strong reputation for helping customers adopt advanced analytical technologies through deep technical expertise and exceptional support.”
TALOS is designed to replace traditional variable pathlength UV workflows with a simpler fixed-path near-infrared measurement approach, noted Hassell. By directly measuring absorption from the peptide backbone, TALOS enables rapid protein quantitation across a wide concentration range without dilution, protein-specific calibration models, extinction coefficient determination, or manual pathlength adjustment, he explained.
“TALOS represents a unique advancement in protein quantitation, enabling rapid, consistent measurements with operational simplicity. These capabilities make it particularly well-suited for modern bioprocessing workflows, from early process development through GMP manufacturing,” said Takao Nakagawa, president, S. T. Japan. “As Japan’s biopharmaceutical industry continues to expand and evolve, TALOS has the potential to make a significant impact, driving efficiencies and reducing complexity across the drug development and manufacturing continuum.”
The post Nirrin Technologies and S.T. Japan Partner on Next-Gen Protein Quantitation Tech appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
Six of the biggest health news stories today
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. There’s a lot of great reporting to share today, so be sure to read all the way through the newsletter. We won’t have a newsletter tomorrow, Juneteenth, so I’ll talk to you again on Monday.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. There’s a lot of great reporting to share today, so be sure to read all the way through the newsletter. We won’t have a newsletter tomorrow, Juneteenth, so I’ll talk to you again on Monday.
Uncategorized
Verastem deprioritizes pancreatic cancer work after ‘decent, but not great’ data shadowed by Revolution
Following the mid-stage readout, Verastem Oncology has decided to move away from its investigational pancreatic cancer drug combo, instead putting resources behind its KRAS inhibitor pill for solid tumors.
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
Nirrin Technologies and S.T. Japan Partner on Next-Gen Protein Quantitation Tech
Six of the biggest health news stories today
Verastem deprioritizes pancreatic cancer work after ‘decent, but not great’ data shadowed by Revolution
Biogen makes up to $1B immuno play with RayThera takeover
GSK, Spero’s oral antibiotic wins first FDA nod for complicated UTI
STAT+: In pancreatic cancer, Patrick Soon-Shiong makes promises he has not kept
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Uncategorized9 years ago
According to Dior Couture, this taboo fashion accessory is back
-
Endpoints News3 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized9 years ago
Phillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years ago
Uber and Lyft are finally available in all of New York State
-
Uncategorized9 years ago
Steph Curry finally got the contract he deserves from the Warriors
-
Contributors9 years ago
The final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized3 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion